TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01591291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron + Brief Behavioral Enhancement Treatment
Description: Ondansetron 4ug/kg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Brief Behavioral Enhancement Treatment
Description: Placebo twice daily
Study: NCT03179150

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography
Description: CT scans were performed on a 128 detector rows CT scanner (Somatom Definition Flash Siemens Medical Systems, Erlangen, Germany) as in routine clinical practice in the centre
Study: NCT02342340

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Navy Beans (cooked)
Description: One time consumption of 3/4 cup of cooked navy beans.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red Kidney Beans (cooked)
Description: One time consumption of 3/4 cup of cooked red kidney beans.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pinto Beans (cooked
Description: One time consumption of 3/4 cup of cooked pinto beans.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Black Beans (cooked)
Description: One time consumption of 3/4 cup of cooked black beans.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lentils (cooked)
Description: One time consumption of 3/4 cup of cooked lentils.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: White Rice
Description: One time consumption of 3/4 cup of cooked white rice.
Study: NCT04226066

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T601
Description: Part1: T601 is injected once (Day1). Dose range: 1E+7, 3E+7, 1E+8, 3E+8, 1E+9pfu.Trial cycle: Day1-21.~For part1, 3+3 dose-escalation. After all patients of one dosage finished DLT evaluation, investigator judged that patients can benefit from treatment and no intolerable toxicity occurred, patients could receive maintenance treatment, and treatment plan is same as Cycle 1.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: T601+5-FC
Description: Part2: T601 is injected once (Day1). Dose range: MTD-2, MTD-1 and MTD of Part1. 5-FC is taken on Day5-18 for 14 consecutive days. Trial cycle: Day1-28.~Part3: T601 is injected 3 times (Day1, 8, 15). Dose range: MTD-1 and MTD, or MTD-2 and MTD-1 of Part2. 5-FC is taken on Day5-7, Day12-14 and Day19-32. Trial cycle: Day1-46.~Part4: Protocol revised based on results of Part1-Part3. Preliminary plan: 30 patients with gastric cancer, pancreatic cancer and hepatocellular cancer who have failed standard therapeutic options are enrolled (10 patients for each indication). Treatment plan is same as Part3.~For part2 and part3, 3+3 dose-escalation. After all patients of one dosage finished DLT evaluation, investigator judged that patients can benefit from treatment and no intolerable toxicity occurred, patients could receive maintenance treatment, and treatment plan is same as Cycle 1.
Study: NCT02508493

Intervention type: OTHER
Intervention: THINC-it Tool
Description: Digitalized cognitive test application administering the following cognitive test components:~* Digit Symbol Substitution Test (DSST)~* Choice Reaction Time (CRT)~* One-back working memory tool~* Trail Making Test B (TMT-B)~* Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)

Intervention type: OTHER
Intervention: THINC-it Tool
Description: Digitalized cognitive test application administering the following cognitive test components:~* Digit Symbol Substitution Test (DSST)~* Choice Reaction Time (CRT)~* One-back working memory tool~* Trail Making Test B (TMT-B)~* Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)
Study: NCT04347148

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SNAGs Treatment
Description: a sustained passive accessory movement (glide), i.e. SNAGs, will be applied by the physiotherapist while the participant will be asked to move actively as allowed by his/her physiological range in the direction producing his symptoms.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Laser Treatment
Description: A Laser YAG 3 Chronic (Winform Medical Engineering s.r.l., San Donà di Piave (VE), Italy), will be detuned and applied in the region of cervical spine in order to have a sham treatment
Study: NCT03980236

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Livongo-Insulia Study App
Description: Throughout the study, participants will be asked to use the LIvongo-Insulia Study App daily to receive their basal insulin dose recommendation. Participants will need to check their before breakfast blood glucose using their Livongo meter. Then, they will need to open the Livongo-Insulia Study App and accept the uploaded blood glucose(s) from the Livongo meter. Once the appropriate information is received, participants will receive an insulin dose recommendation and should confirm once the dose has been taken. Depending on their blood glucose, participants may also receive coaching messages and coaching support from the Livongo program.
Study: NCT01780428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CL-108 (hydrodocone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CL-108 (hydrodocone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01204879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Participants earn the chance to win prizes for the targeted behavior.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management
Description: Participants earn the chance to win prizes for the targeted behavior.
Study: NCT00915915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol/Gestodene (BAY86-5016)
Description: Transdermal patch: 0.55mg Ethinylestradiol (EE+2.1mg GSD)Gestodene; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles), 1 Follow - up cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol/Gestodene (BAY86-5016)
Description: Transdermal patch: 0.55mg Ethinylestradiol (EE+1.05mg GSD)Gestodene; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles), 1 Follow - up cycle)
Study: NCT00954356

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single oral administration of 5 x 100 mg Placebo capsules.
Study: NCT02399072

Intervention type: OTHER
Intervention: No intervention
Description: No intervention administered in this study
Study: NCT02122965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication review
Description: Medication review is a structured, critical examination of a patient's medications with the objective of reaching agreement with the patient about treatment, optimizing the medications' impact, and minimizing the number of medication-related problems and adverse drug events.
Study: NCT02251574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Calorie Diet
Description: Weight management program designed around a low calorie diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet
Description: Weight management program designed around a very low calorie diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Care provided that would normally be given to people meeting eligibility criteria for this study.
Study: NCT00187148

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: EnvDNA
Description: administered as 100 mcg of DNA in 1.5mL PBS every 28 days for 3 injections
Study: NCT04126187

Intervention type: DEVICE
Intervention: Panoptix
Description: Panoptix trifocal intraocular lens (IOL)
Study: NCT03673631

Intervention type: DEVICE
Intervention: NIV
Description: NIV setting: minimal FiO2 0.3; tidal volume 6-8ml/kg (theoretical body weight)

Intervention type: DEVICE
Intervention: NIV
Description: NIV setting: minimal FiO2 0.3; tidal volume 6-8ml/kg (theoretical body weight)

Intervention type: DEVICE
Intervention: NFHC-O2
Description: NFHC-O2 setting: minimal FiO2 0.3; minimal flow 40l/min

Intervention type: DEVICE
Intervention: NFHC-O2
Description: NFHC-O2 setting: minimal FiO2 0.3; minimal flow 40l/min
Study: NCT02503111

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Hyfrecator ® 2000 Electrosurgical System
Description: Lesion is ablated by the The Hyfrecator ® 2000 Electrosurgical System. During electrocautery (EC) with The Hyfrecator, a gentle brushing technique occurs and the tissue is removed with forceps.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation Alone
Description: No treatment to AIN-2 or AIN-3, only active surveillance.
Study: NCT00033514

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Day 1 4mg/kg IV 2 mg/kg IV weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: 100 mg daily on Course 1 Day 2. After three weeks patients who have not experienced specific adverse events, dose will be escalated to 150 mg daily. Patients who have experienced specific adverse events dose will remain 100 mg daily or dose reduced as necessary per protocol.
Study: NCT01028794

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous bone marrow mononuclear cells
Description: intravenous administration of autologous bone marrow derived mononuclear cells obtained from 25ml of bone marrow on day 7-10 after stroke (only once in that period)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous bone marrow mononuclear cells
Description: intravenous administration of autologous bone marrow derived mononuclear cells obtained from 50ml of bone marrow on day 7-10 after stroke (only once in that period)
Study: NCT01845337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teysuno

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teysuno
Study: NCT03524586

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ipsilateral rotation of head
Description: Ipsilateral rotation of head against fixed tube

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Contralateral rotation of head
Description: Contralateral rotation of head against fixed tube
Study: NCT03576456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam 0.5 mg
Description: receive alprazolam prior to angio

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: receive placebo prior to angio
Study: NCT03312127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ILIAC ENDOPROSTHESIS GORE EXCLUDER
Description: Set up of GORE ® Excluder Iliac Branch Endoprosthesis in endovascular barring of complex aneurysms without distal neck. In the immediate post-operating follow-up visit and at the 3 months visit and the 12 months visit after surgery, an ultra-sound scan, a tomodensitometric exam and a walking test on a treadmill with oximetric gluteal region exploration will systematically be performed.
Study: NCT02073149

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose iron as NaFeEDTA
Description: Daily home fortification for 30 days with 3 mg iron as NaFeEDTA, vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Conventional dose iron as ferrous salt
Description: Daily home fortification for 30 days with 12.5 mg iron as encapsulated ferrous fumarate, vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily home fortification for 30 days with vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
Study: NCT02508493

Intervention type: OTHER
Intervention: Pencil-and-paper Cognitive Tests
Description: Pencil-and-paper versions of the following cognitive tests:~* Digit Symbol Substitution Test (DSST)~* Trail Making Test B (TMT-B)~* Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)~* Variant of Choice Reaction Time (CRT)~* Variant of the One-back working memory tool

Intervention type: OTHER
Intervention: Pencil-and-paper Cognitive Tests
Description: Pencil-and-paper versions of the following cognitive tests:~* Digit Symbol Substitution Test (DSST)~* Trail Making Test B (TMT-B)~* Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)~* Variant of Choice Reaction Time (CRT)~* Variant of the One-back working memory tool
Study: NCT01913275

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic stenting
Description: Endoscopic stenting to decrease preopertaive jaundice

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cholecystojejunostomy
Description: surgical procedure to decrease preoperative jaundice
Study: NCT03125460

Intervention type: DEVICE
Intervention: Xpert Bladder Cancer Monitor
Description: in vitro diagnostic test for the recurrence of bladder cancer in patients that have been previously diagnosed with bladder cancer
Study: NCT00391911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetylcysteine
Description: Patients are assigned to either N-Acetylcysteine or placebo. Dose is weight based Placebo is normal saline or D5W

Intervention type: OTHER
Group type: OTHER
Intervention: N-Acetylcystine and Non CRRT
Description: Patients are assigned to N-Acetylcysteine and CRRT. The N-Acetylcysteine is blinded to everyone except pharmacy. The CRRT is open label as would be impossible to blind

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo and CRRT
Description: Patients are assigned to Placebo and CRRT. The N-Acetylcysteine/Placebo is blinded to everyone except pharmacy. The CRRT is open label

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo and Non CRRT
Description: Patients are assigned to Placebo and non-CRRT. The N-Acetylcysteine/placebo is blinded to everyone except pharmacy. The CRRT/non CRRT is open label as would be impossible to blind
Study: NCT04044625

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-intensity NPPV
Description: In the high-intensity NPPV group, patients will undergo pressure-limited NPPV (eg, NPPV in spontaneous/timed mode) at a higher IPAP level. IPAP is initially set at 10 cmH2O and continuously adjusted by increments and decrements of 1-2 cmH2O (typically ranging between 20 and 30 cmH2O), according to patients' tolerance, to obtain a tidal volume (VT) of 10-15 mL/kg. IPAP should be increased as much as possible to decrease PaCO2 to a normal level. However, if PaCO2 decreases to less than 35 mmHg, IPAP should be decreased to achieve normocapnia.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity NPPV
Description: In the low-intensity NPPV group, patients will undergo pressure-limited NPPV (eg, NPPV in spontaneous/timed mode) with a conventional IPAP level. IPAP is initially set to 10 cmH2O and is continuously adjusted by increments and decrements of 1-2 cmH2O (up to 20 cmH2O), according to patients' tolerance, to obtain a VT of 6-10 mL/kg.
Study: NCT01756209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium 400Mg
Description: magnesium 400 mg + conventional treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium 400Mg
Description: magnesium 400 mg + conventional treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 10 mg/kg
Description: ibuprofen 10 mg/kg oral single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 10 mg/kg
Description: ibuprofen 10 mg/kg oral single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen 15 mg/kg
Description: Acetaminophen 15 mg/kg oral single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen 15 mg/kg
Description: Acetaminophen 15 mg/kg oral single dose
Study: NCT02802527

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous Tracheostomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous Tracheostomy
Study: NCT04284579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IV cannula
Description: We measure the time duration needed for IV cannulation
Study: NCT04035369

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tap and Inject (TAI)
Description: Patients randomized to the TAI group will have a 0.2 mL vitreous specimen collected and a 0.1 mL anterior chamber paracentesis performed to be sent for standard cultures, Gram stain, and sensitivities.~Intravitreal injection of the following antibiotics: Vancomycin 1.0 mg/0.1 mL, ceftazidime 2.25 mg/0.1 mL (amikacin 400 mcg/0.1 mL instead of Ceftazidime if severe penicillin allergy) and an intravitreal injection of dexamethasone 400 mcg/0.1 mL
Study: NCT03225924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib
Description: 200mg or 400mg twice a day for 7 days every 21 cycles - total of 8 cycles
Study: NCT04035369

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars Plana Vitrectomy (PPV)
Description: Patients randomized to the PPV group will undergo a three-port PPV. The patient should be added to the OR list as an A-case (maximum 6 hours wait) and no intravitreal injection should be performed prior to the surgery. A 0.1 mL aqueous humor simple immediately before the surgery. A 0.2 mL vitreous specimen will be obtained after the sclerotomies are placed. The PPV procedure should be limited to core vitrectomy, air fluid exchange and intravitreal injections (antibiotics and dexamethasone - Vancomycin 1.0 mg/0.1 mL, ceftazidime 2.25 mg/0.1 mL or amikacin 400 mcg/0.1 mL instead of Ceftazidime if severe penicillin allergy and an intravitreal injection of dexamethasone 400 mcg/0.1 mL). Other tamponades such as silicone oil should be avoided if possible. The PPV will then be completed by the surgeon and the vitreous specimen will be sent for standard cultures, Gram stain, and sensitivities.
Study: NCT00336960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: twice daily beginning 5 days prior to radiotherapy and continuing until completion of radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Patients receive concurrent fluorouracil IV continuously for 5 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: 4-10 weeks after completion of chemoradiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo radiotherapy 5 days a week for 5 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tumor biopsy
Description: at baseline and then at the time of surgical resection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: blood and urine collected at baseline, 5 days after initiation of celecoxib, 7 days after initiation of celecoxib in combination with fluorouracil and radiotherapy, and at the time of surgical resection. specimens are evaluated for COX-2 expression, eicosanoid production, and gene and protein expression using immunohistochemistry, microarray, and mass spectrometry.
Study: NCT02165735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patient activation training
Description: Patient activation training involves six, 90-minute, group (8-12 person) training sessions facilitated by trained peers and training staff and one (20-30 minute) pre-visit coaching session conducted by staff. The hands on group training includes: 1) HIV education; 2) use of a handheld smart device; 3) use of an HIV electronic personal health record app that runs on the smart device; 4) identification of patients' visit need priorities and skills for communicating with their HIV provider. The pre-visit coaching includes identification of patient concerns and patient behavioral rehearsal for asking about these concerns.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual HIV care
Study: NCT00101283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: 500 mg/m2 IV over 10 minutes on day 1 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: 500 mg/m2 IV over 10 minutes on day 1 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given by IV over 30 minutes at an area under the curve (AUC) of 5 on day 1 of a 21-day cycle
Study: NCT02174458

Intervention type: PROCEDURE
Intervention: Body Contouring Surgery
Description: Patients after bariatric surgery (BS) and patients with no history of BS but after natural weight loss and some degree of skin laxity who underwent Body contouring will be included after written informed consent is obtained.
Study: NCT02210936

Intervention type: OTHER
Group type: OTHER
Intervention: Educational Intervention
Description: The design is primarily a pre-post, non-equivalent comparison group test of program effectiveness. If final sample size permits, we will examine program effects for each practice environment separately. For measures that require interview data there will be no comparison group data.~We will construct matched comparison groups of physicians for each environment for which only secondary data analysis will be conducted. The matched comparison group will be constructed using prescription data from the DoD's pharmacy data transaction system (MACH and DORN VAMC) and from SCRIPTS (community-based physicians and VA prescribers).
Study: NCT03225924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: cycles of 21 days - 375mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: cycles of 21 days - 750 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: cycles of 21 days - 50mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: cycles of 21 days - 1.4mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: cycles of 21 days - 40mg/m²
Study: NCT00082381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide (AC2993)
Description: subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 22 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: subcutaneous injection, once daily; forced titration to target blood glucose level
Study: NCT04129385

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 20 degree Trendelenburg position
Description: The patients in the intervention group will be placed in trendelenburg position postoperatively.
Study: NCT02505360

Intervention type: OTHER
Group type: OTHER
Intervention: Measurements of concentration of hyaluronic acid as well as in type 1 collagen and 3
Study: NCT00556270

Intervention type: DRUG
Intervention: Matrifen
Description: as defined in the Summary of Product Characteristics (Fachinformation Chapter 4.2)